Skip to main content
. Author manuscript; available in PMC: 2015 Mar 16.
Published in final edited form as: J Immunol. 2011 Dec 2;188(1):294–301. doi: 10.4049/jimmunol.1101590

Figure 4.

Figure 4

Anti-Gr1 treatment reduced insulitis and prevented type 1 diabetes development in NOD mice. 9 week-old female NOD mice were injected with one dose of 0.25mg anti-Gr1 or control IgG antibody intravenously. Diabetes development was monitored by testing for glycosuria twice a week. Disease was confirmed by a blood glucose level greater than 250 mg/dl. A) Diabetes incidence in mice treated with anti-Gr1 or control IgG antibody (n=10 each group, Log-rank test P=0.0455). B) and C) Insulitis in mice treated with anti-Gr1 or control IgG antibody (n=5 each group), was scored using the system outlined in the methods, χ2 test (p< 0.03).